21.05.2012 - British Bicycle Therapeutics plc (Cambridge) named Rolf Günther as its new Chief Executive Officer in April. Under the former CEO and COO of Affimed, Bicycle will offer drug discovery partners its proprietary bicyclic peptide technology, which combines the benefits of small molecules with the selectivity of biopharmaceuticals.
The technology platform allows affinity selection of peptides displayed on the surfaces of phages that are linked to an organic scaffold. Günther has more than 21 years of pharmaceutical industry experience, with an extensive background in drug development, biologics and speciality pharmaceuticals. At Affimed, he successfully developed the antibody specialist’s clinical product portfolio in oncology. Günther will continue to be engaged as COO at Affimed in a part-time position until August. He has also held the position of VP and General Manager of the Critical Care business unit of Aventis Behring, which he joined in 1996, and has been responsible for successful drug approvals in both the US and Europe.